• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血尿酸与 2 型糖尿病肾病发病及进展的相关性。

Correlations between blood uric acid and the incidence and progression of type 2 diabetes nephropathy.

机构信息

Department of Endocrinology, The First People's Hospital of Wujiang District Suzhou, Suzhou, China.

出版信息

Eur Rev Med Pharmacol Sci. 2018 Jan;22(2):506-511. doi: 10.26355/eurrev_201801_14202.

DOI:10.26355/eurrev_201801_14202
PMID:29424910
Abstract

OBJECTIVE

To investigate the relationships between blood uric acid (BUA) level and the incidence, progression and deterioration of diabetic nephropathy (DN) in patients with type 2 diabetes mellitus (T2DM).

PATIENTS AND METHODS

A total of fifty patients with T2DM alone whose glycosylated hemoglobin (HbA1c) were under normal range (4-6.5%) at their admission to our hospital were randomly selected as diabetes mellitus (DM) group. Fifty patients with hyperuricemia alone were randomly selected as hyperuricemia (HUA) group. Fifty patients with T2DM complicated with hyperuricemia who were admitted to the hospital with HbAlc of 4-6.5% were randomly selected as diabetes mellitus hyperuricemia (DM-HUA) group. In addition, fifty healthy persons who passed the health examination were randomly selected as normal control (NC) group. The general data such as name and body mass index (BMI), metabolic-related indexes such as fasting blood glucose (FBG), total cholesterol (TC) and triglyceride (TG) as well as kidney-related indexes such as blood urea nitrogen (BUN), creatinine (Cr) and albumin-creatinine-ratio (ACR) in four groups were tested and recorded at the same time. The interrelationships between uric acid (UA) and the above indexes were statistically analyzed.

RESULTS

In DM-HUA group, serum TC, TG and low density lipoprotein (LDL) as well as urine ACE were greatly increased (p<0.05) compared with the other three groups, high-density lipoprotein (HDL) was significantly decreased compared with the remaining three groups (p<0.05), and BMI and Cr were increased compared with those in NC group and DM group (p<0.05). There were no significant differences in metabolic indexes and renal functions in DM group and HUA group. Compared with NC group, TC, LDL, serum β2 macroglobulin and BMI in above two groups were greatly increased (p<0.05); BUN and Cr in HUA group were slightly higher than those in NC group (p<0.05). Multiple linear regression analysis showed that UA level was the main factor affecting ACR (R2=0.636, p<0.001).

CONCLUSIONS

UA level is an independent risk factor for early renal disease in patients with T2DM, which can promote the progression and deterioration of renal disease in T2DM patients.

摘要

目的

探讨血尿酸(BUA)水平与 2 型糖尿病(T2DM)患者糖尿病肾病(DN)的发生、进展和恶化的关系。

方法

选取我院收治的糖化血红蛋白(HbA1c)正常范围(4-6.5%)的单纯 T2DM 患者 50 例作为糖尿病组(DM 组),单纯高尿酸血症(HUA)患者 50 例作为高尿酸血症组(HUA 组),T2DM 合并 HUA 患者 50 例作为糖尿病高尿酸血症组(DM-HUA 组),同期选择我院体检健康者 50 例作为正常对照组(NC 组)。同时检测并记录四组患者的一般资料(姓名、体质量指数(BMI))、代谢相关指标(空腹血糖(FBG)、总胆固醇(TC)、三酰甘油(TG))及肾脏相关指标(血尿素氮(BUN)、肌酐(Cr)、白蛋白-肌酐比(ACR)),并对尿酸(UA)与上述指标的相关性进行统计学分析。

结果

DM-HUA 组患者血清 TC、TG、低密度脂蛋白(LDL)及尿 ACE 较其他三组明显升高(p<0.05),高密度脂蛋白(HDL)较其余三组明显降低(p<0.05),且 BMI 和 Cr 较 NC 组和 DM 组升高(p<0.05);DM 组和 HUA 组的代谢指标和肾功能无明显差异。与 NC 组相比,两组 TC、LDL、血清β2 微球蛋白和 BMI 明显升高(p<0.05),HUA 组 BUN 和 Cr 略高于 NC 组(p<0.05)。多元线性回归分析显示,UA 水平是影响 ACR 的主要因素(R2=0.636,p<0.001)。

结论

UA 水平是 T2DM 患者早期肾病的独立危险因素,可促进 T2DM 患者肾病的进展和恶化。

相似文献

1
Correlations between blood uric acid and the incidence and progression of type 2 diabetes nephropathy.血尿酸与 2 型糖尿病肾病发病及进展的相关性。
Eur Rev Med Pharmacol Sci. 2018 Jan;22(2):506-511. doi: 10.26355/eurrev_201801_14202.
2
[Effect of Serum Uric Acid on Renal Function of Patients with Abnormal Glucose Metabolism].[血清尿酸对糖代谢异常患者肾功能的影响]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2015 Sep;46(5):754-8.
3
The diagnostic value of lipoprotein-associated phospholipase A2 in early diabetic nephropathy.脂蛋白相关磷脂酶 A2 在早期糖尿病肾病中的诊断价值。
Ann Med. 2023;55(2):2230446. doi: 10.1080/07853890.2023.2230446.
4
Correlation between remnant cholesterol and hyperuricemia in patients with type 2 diabetes mellitus: a cross-sectional study.2 型糖尿病患者残余胆固醇与高尿酸血症的相关性:一项横断面研究。
Lipids Health Dis. 2024 May 25;23(1):155. doi: 10.1186/s12944-024-02148-3.
5
Hyperuricemia and albuminuria in patients with type 2 diabetes mellitus.2型糖尿病患者的高尿酸血症和蛋白尿
Iran J Kidney Dis. 2011 Jan;5(1):21-4.
6
Clinical Features and Microvascular Complications Risk Factors of Early-onset Type 2 Diabetes Mellitus.早发型 2 型糖尿病的临床特征及微血管并发症危险因素。
Curr Med Sci. 2019 Oct;39(5):754-758. doi: 10.1007/s11596-019-2102-7. Epub 2019 Oct 14.
7
[Association of elevated uric acid with metabolic disorders and analysis of the risk factors of hyperuricemia in type 2 diabetes mellitus].[高尿酸血症与代谢紊乱的关联及2型糖尿病患者高尿酸血症危险因素分析]
Nan Fang Yi Ke Da Xue Xue Bao. 2011 Mar;31(3):544-7.
8
Genomic DNA Methylation in Diabetic Chronic Complications in Patients With Type 2 Diabetes Mellitus.2 型糖尿病患者糖尿病慢性并发症的基因组 DNA 甲基化。
Front Endocrinol (Lausanne). 2022 Jun 29;13:896511. doi: 10.3389/fendo.2022.896511. eCollection 2022.
9
The changes in miR-130b levels in human serum and the correlation with the severity of diabetic nephropathy.人血清中miR-130b水平的变化及其与糖尿病肾病严重程度的相关性。
Diabetes Metab Res Rev. 2015 Oct;31(7):717-24. doi: 10.1002/dmrr.2659. Epub 2015 Jun 25.
10
[Associations Between Insulin Resistance Indexes and Hyperuricemia in Hypertensive Population].高血压人群中胰岛素抵抗指数与高尿酸血症的关联
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2023 Jun;45(3):390-398. doi: 10.3881/j.issn.1000-503X.15414.

引用本文的文献

1
Anti-diabetes activity of (R)-gentiandiol in KKAy type 2 mice.(R)-龙胆二醇对KKAy 2型小鼠的抗糖尿病活性
Sci Rep. 2025 May 6;15(1):15730. doi: 10.1038/s41598-025-00422-7.
2
J-shaped association of serum uric acid with all-cause and cardiovascular mortality in patients with diabetic kidney disease.糖尿病肾病患者血清尿酸与全因死亡率和心血管死亡率的J形关联。
Acta Diabetol. 2025 Apr;62(4):511-521. doi: 10.1007/s00592-024-02376-0. Epub 2024 Nov 14.
3
Insights into the Novel Biomarkers Expressed in Diabetic Nephropathy: Potential Clinical Applications.
糖尿病肾病中表达的新型生物标志物的见解:潜在的临床应用。
Curr Pharm Des. 2025;31(8):619-629. doi: 10.2174/0113816128333694240928161703.
4
Cardioprotective effects of aerobic training in diabetic rats: Reducing cardiac apoptotic indices and oxidative stress for a healthier heart.有氧运动训练对糖尿病大鼠的心脏保护作用:降低心脏凋亡指数和氧化应激以促进心脏更健康
ARYA Atheroscler. 2024 Mar-Apr;20(2):50-60. doi: 10.48305/arya.2024.41976.2911.
5
Hippo/YAP signaling pathway: a new therapeutic target for diabetes mellitus and vascular complications.河马/Yes相关蛋白信号通路:糖尿病及血管并发症的新治疗靶点。
Ther Adv Endocrinol Metab. 2023 Dec 25;14:20420188231220134. doi: 10.1177/20420188231220134. eCollection 2023.
6
Clinical and Pharmacotherapeutic Profile of Patients with Type 2 Diabetes Mellitus Admitted to a Hospital Emergency Department.入住医院急诊科的2型糖尿病患者的临床和药物治疗概况
Biomedicines. 2023 Jan 18;11(2):256. doi: 10.3390/biomedicines11020256.
7
New comprehensive reference values for kidney function indexes across adult and geriatric ages in Chinese popuplation.中国人群成人及老年阶段肾功能指标的新综合参考值
Heliyon. 2022 Nov 30;8(12):e11919. doi: 10.1016/j.heliyon.2022.e11919. eCollection 2022 Dec.
8
Development and internal validation of a risk model for hyperuricemia in diabetic kidney disease patients.糖尿病肾病患者高尿酸血症风险模型的建立与内部验证。
Front Public Health. 2022 Oct 19;10:863064. doi: 10.3389/fpubh.2022.863064. eCollection 2022.
9
The perirenal fat thickness was independently associated with serum uric acid level in patients with type 2 diabetes mellitus.肾周脂肪厚度与 2 型糖尿病患者的血清尿酸水平独立相关。
BMC Endocr Disord. 2022 Aug 20;22(1):210. doi: 10.1186/s12902-022-01081-9.
10
Serum Uric Acid Levels and Risk of Rapid Decline of Estimated Glomerular Filtration Rate in Patients with Type 2 Diabetes: Findings from a 5-Year Prospective Cohort Study.2型糖尿病患者血清尿酸水平与估算肾小球滤过率快速下降风险:一项5年前瞻性队列研究的结果
Healthcare (Basel). 2021 Oct 9;9(10):1341. doi: 10.3390/healthcare9101341.